Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite the fact that the adjuvant properties of the heat-labile enterotoxins of Escherichia coli(LT) and Vibrio cholerae(CT) have been known for more than 20 years, there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins. A number of attempts with various degrees of success have been made to reduce or eliminate the enterotoxicity of LT and CT so they can safely be used as oral adjuvants or immunogens. In this report we characterize the structural, enzymatic, enterotoxic, and adjuvant properties of a novel mutant of LT, designated LT(R192G/L211A), or dmLT. dmLT was not sensitive to trypsin activation, had reduced enzymatic activity for induction of cyclic AMP in Caco-2 cells, and exhibited no enterotoxicity in the patent mouse assay. Importantly, dmLT retained the ability to function as an oral adjuvant for a coadministered antigen (tetanus toxoid) and to elicit anti-LT antibodies.In vitro and in vivo data suggest that the reduced enterotoxicity of this molecule compared to native LT or the single mutant, LT(R192G), is a consequence of increased sensitivity to proteolysis and rapid intracellular degradation in mammalian cells. In conclusion, dmLT is a safe and powerful detoxified enterotoxin with the potential to function as a mucosal adjuvant for coadministered antigens and to elicit anti-LT antibodies without undesirable side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, a double-mutant labile toxin (dmLT) derived from Escherichia coli is a potent adjuvant that can enhance immune responses to IPV [113,114,115,116].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030595 · Cited by 916 · cited 1×
“Intranasal use of these molecules or their mutants in humans has serious safety risks and has been associated with Bell’s palsy (21, 27).”
BackgroundNew knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
Levine, M. M., Kaper, J. B., Black, R. E., & Clements, M. L. (1983) · Microbiological Reviews · doi:10.1128/mmbr.47.4.510-550.1983 · Cited by 636
Intestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18326 · Cited by 572 · cited 1×
“In intestinal epithelial cells, this induction of cAMP causes a disregulation of cAMP-sensitive ion transport mechanisms, inhibiting intracellular salt absorption, increasing electrolyte transport into the gut lumen, and creating an osmotic gradient favoring intestinal water secretion (12).”
BackgroundProtein Disulfide Isomerase Acts as a Redox-Dependent Chaperone to Unfold Cholera Toxin
Tsai, B., Rodighiero, C., Lencer, W. I., & Rapoport, T. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00289-6 · Cited by 483 · cited 3×
“Tsai et al. demonstrated that protein disulfide isomerase (PDI) in the lumen of the ER functions to disassemble and unfold CT (and presumably LT) once its A-chain has been proteolytically cleaved at Arg192 (38).”
BackgroundInfluentialIntestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318326 · Cited by 468
Dickinson, B. L., & Clements, J. D. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1617-1623.1995 · Cited by 350 · cited 5×
“chromatography in our laboratory as described previously (6, 8, 34).”
BackgroundMethodInfluentialSelf-citationClements, J. D., & Finkelstein, R. A. (1979) · Infection and Immunity · doi:10.1128/iai.24.3.760-769.1979 · Cited by 330 · cited 2×
“chromatography in our laboratory as described previously (6, 8, 34).”
MethodResultSelf-citationMichetti, P., Kreiss, C., Kotloff, K. L., Porta, N., Blanco, J., Bachmann, D., Herranz, M., Saldinger, P. F., Corthésy–Theulaz, I., Losonsky, G., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70063-6 · Cited by 310
Lewis, D. J. M., Huo, Z., Barnett, S., Kromann, I., Giemza, R., Galiza, E., Woodrow, M., Thierry-Carstensen, B., Andersen, P., Novicki, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006999 · Cited by 305 · cited 1×
“Intranasal use of these molecules or their mutants in humans has serious safety risks and has been associated with Bell’s palsy (21, 27).”
BackgroundClements, J. D., Hartzog, N. M., & Lyon, F. L. (1988) · Vaccine · doi:10.1016/0264-410x(88)90223-x · Cited by 284 · cited 1×
“Despite the fact that the adjuvant properties of LT and CT have been known for more than 20 years (7, 11), there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins.”
BackgroundSelf-citation
Research works printed but not linked: 1
- Oplinger, 1997, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. G-10
Cited by
Recent Advances in Understanding Enteric Pathogenic Escherichia coli
Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., & Finlay, B. B. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-13 · Cited by 1,569
“A recent study characterized a new mutant LT called dmLT that is quickly degraded, has reduced toxicity, and may be useful in oral vaccines (774).”
BackgroundMucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems
Boyaka, P. N. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601775 · Cited by 257
“Approaches used to dissociate the toxicity and the adjuvanticity of the bacterial toxins included partial or complete inactivation of the enzymatic activity of CT (59) and LT (60).”
Status of vaccine research and development for Shigella
Mani, S., Wierzba, T., & Walker, R. I. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.075 · Cited by 229
Pokharel, P., Dhakal, S., & Dozois, C. M. (2023) · Microorganisms · doi:10.3390/microorganisms11020344 · Cited by 207
Metadata
- Authors
- Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D.
- Affiliations
- Tulane University (US)
- Corresponding author
- Clements, John D.
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2011-02-02
- Volume
- 18
- Issue
- 4
- Pages
- 546-551
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- PMC
- PMC3122563
- OpenAlex
- W2133080338
- Cited by
- 221
- References
- 40
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 2 · 2023: 25 · 2022: 8 · 2021: 10 · 2020: 13 · 2019: 14 · 2018: 20 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 18 · 2013: 17 · 2012: 16
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Clinical and Vaccine Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Louisiana Board of Regents
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering (EB006493-04, R01EB006493)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- heat-labile enterotoxin, Escherichia coli, oral adjuvant, trypsin activation, enterotoxicity, tetanus toxoid, mucosal immunization, intracellular degradation, proteolysis
- MeSH terms
- Adjuvants, Immunologic, Administration, Oral, Animals, Antibodies, Bacterial, Antitoxins, Bacterial Toxins, Enterotoxins, Female, Humans, Mice, Inbred BALB C, Tetanus Toxoid, Caco-2 Cells, Amino Acid Substitution, Escherichia coli Proteins, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant. https://app.cochat.ai/papers/10.1128/cvi.00538-10
- The paper
- Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D. (2011). Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant. Clinical and Vaccine Immunology. https://doi.org/10.1128/cvi.00538-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.